- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02523144
Dexmedetomidine in Children Having Transthoracic Echocardiography
28 juli 2017 uppdaterad av: Children's Hospital Medical Center, Cincinnati
A Qualitative Comparison of Oral Chloral Hydrate vs 2.0 or 3.0 mcg/kg Nasal Dexmedetomidine in Children Undergoing Transthoracic Echocardiography
Sedation Techniques for children undergoing transthoracic echocardiography (TTE).
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The goal in this study is to determine if there is a significant difference in the quality of sedation between two standard sedation techniques and between two doses of dexmedetomidine for children undergoing (TTE).
Studietyp
Interventionell
Inskrivning (Faktisk)
279
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Shanghai, Kina
- Shanghai Children's Hospital
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
3 månader till 3 år (Barn)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Outpatients scheduled to receive sedation for transthoracic echocardiography
- Subject must be a candidate for both types of anesthetic and both doses of dexmedetomidine
- Must be 3 months to 36 months of age
Exclusion Criteria:
- The subject has a history of cardiac conduction system disease (e.g. 1st or 2nd degree AV block) or channelopathy (e.g. long QT).
- The subject is taking digoxin, alpha-adrenergic or beta-adrenergic agonist or antagonist (e.g., clonidine, propranolol, albuterol), anti-arrhythmic medications, or vasodilators (e.g. ACE inhibitors)
- The subject has received a dose of any other sedative within 48 hours.
- The subject has life-threatening, medical conditions (American Society of Anesthesiologists Physical Status 4, 5). The American Society of Anesthesiologists (ASA) classification scale is a measure of physical status or how healthy the patient is. For our study, we will focus on children which are defined as ASA I, II or III which means a healthy child (ASA I), a child with a systemic disease that is mild and well controlled (ASA II) or a child with systemic disease that is severe and controlled (ASA III).
- The subject is allergic to or has a contraindication to any of the drugs used in the study.
- The subject has previously been treated under this protocol.
- The subject has severe coarctation of the aorta (risk of exaggerated vasoconstriction)
- The subject has Moyamoya disease (risk of recurrent stroke)
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Chloral Hydrate + placebo
Oral chloral hydrate sedation in flavored syrup plus nasal saline placebo
|
70mg/kg chloral hydrate
Flavored placebo syrup
|
|
Aktiv komparator: Dexmedetomidine 2mcg/kg + placebo
Nasal dexmedetomidine sedation 2 mcg/kg plus oral flavored syrup placebo
|
Flavored placebo syrup
2mcg/kg
3mcg/kg
|
|
Aktiv komparator: Dexmedetomidine 3mcg/kg + placebo
Nasal dexmedetomidine sedation 3 mcg/kg plus oral flavored syrup placebo
|
Flavored placebo syrup
2mcg/kg
3mcg/kg
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to sedation
Tidsram: 30 minutes
|
Achieve Ramsay sedation >3 within 30 minutes of administration of drug
|
30 minutes
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Duration of sedation level >3
Tidsram: Patients will be followed for the duration of the procedure, average of 1 hour
|
Patients will be followed for the duration of the procedure, average of 1 hour
|
|
|
The number of sonographer pauses
Tidsram: Participants will be followed for the duration of the procedure, average of 1 hour
|
The number of sonographer pauses over 2 minutes due to patient movement or medical interventions will be counted
|
Participants will be followed for the duration of the procedure, average of 1 hour
|
|
Need for rescue dexmedetomidine
Tidsram: Participants will be followed for the duration of the procedure, average of 1 hour
|
The incidence of need for rescue nasal dexmedetomidine, due to patient arousal or movement prior to completion of TTE.
|
Participants will be followed for the duration of the procedure, average of 1 hour
|
|
Incidence of respiratory complications
Tidsram: Participants will be followed for the duration of the hospital stay, average of 2 hours
|
Documentation of the incidence of respiratory complications
|
Participants will be followed for the duration of the hospital stay, average of 2 hours
|
|
Vital sign deviations of more than 30% from baseline
Tidsram: Participants will be followed for the duration of the hospital stay, average of 2 hours
|
Documentation of the incidence of blood pressure or heart rate deviations of more than 30% from baseline.
Baseline will be measured prior to sedative administration.
|
Participants will be followed for the duration of the hospital stay, average of 2 hours
|
|
Post anesthesia drowsiness
Tidsram: Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the incidence of post anesthesia drowsiness
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
|
Duration of Post Anesthesia Care Unit phase
Tidsram: Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the stay in Post Anesthesia Care Unit in minutes
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
|
Time to oral fluid intake
Tidsram: Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the time (in minutes) to oral fluid intake during the PACU phase
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
|
Time to discharge
Tidsram: Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the hospital stay after completion of the TTE.
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
|
Satisfaction of parents
Tidsram: Up to 3 days
|
The satisfaction of the sedation technique will be completed by the parents by asking a series of questions during a follow-up phone call the next business day after the TTE.
|
Up to 3 days
|
|
Severity of respiratory complications
Tidsram: Participants will be followed for the duration of the hospital stay, average of 2 hours
|
Documentation of the severity of respiratory complications
|
Participants will be followed for the duration of the hospital stay, average of 2 hours
|
|
Post anesthesia agitation
Tidsram: Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the incidence of post anesthesia agitation
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Jeffrey Miller, MD, Children's Hospital Medical Center, Cincinnati
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 september 2014
Primärt slutförande (Faktisk)
1 maj 2017
Avslutad studie (Faktisk)
1 maj 2017
Studieregistreringsdatum
Först inskickad
27 juli 2015
Först inskickad som uppfyllde QC-kriterierna
13 augusti 2015
Första postat (Uppskatta)
14 augusti 2015
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
31 juli 2017
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
28 juli 2017
Senast verifierad
1 juli 2017
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Hjärt-kärlsjukdomar
- Hjärtsjukdom
- Läkemedels fysiologiska effekter
- Adrenerga medel
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Depressiva medel i centrala nervsystemet
- Agenter från det perifera nervsystemet
- Analgetika
- Sensoriska systemagenter
- Analgetika, icke-narkotiska
- Adrenerga alfa-2-receptoragonister
- Adrenerga alfa-agonister
- Adrenerga agonister
- Hypnotika och lugnande medel
- Dexmedetomidin
- Kloralhydrat
Andra studie-ID-nummer
- SCMCIRB-K2014057
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .